Gene · 5004
ORM1: orosomucoid 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ORM1: orosomucoid 1. Genes, record 5004. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5004
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P02763 | Alpha-1-acid glycoprotein 1 | 201 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents68
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 56646 | P02763 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 1742 | P02763 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 9821 | P02763 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 1742 | P02763 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 9821 | P02763 | Espacenet |
| EP 4505469 A2 | 2025-02-12 | 124 | P02763 | Espacenet |
| EP 4505469 A2 | 2025-02-12 | 125 | P02763 | Espacenet |
| EP 4505469 A2 | 2025-02-12 | 158 | P02763 | Espacenet |
| EP 4505469 A2 | 2025-02-12 | 200 | P02763 | Espacenet |
| EP 4505469 A2 | 2025-02-12 | 27 | P02763 | Espacenet |
1 to 10 of 68
See all 68 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants986
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ORM1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA006973 | Regional Oncology Research Center | 4 | 2025 |
| ZIAHL006001 | Framingham Project/Levy | 4 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| P20GM113226 | Hepatobiology and Toxicology COBRE | 2 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 2 | 2025 |
| P30CA012197 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016059 | Massey Cancer Center - Cancer Center Support Grant | 2 | 2025 |
| P30CA022453 | CANCER CENTER SUPPORT GRANT | 2 | 2025 |
| P30CA044579 | University of Virginia Cancer Center Support Grant | 2 | 2025 |
| P30CA051008 | Georgetown University Lombardi Comprehensive Cancer Center Support Grant | 2 | 2025 |
1 to 10 of 986Source NIH's project files
See all 986 nih grantsPapers1,766
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Plasma protein profile in patients with antiphospholipid syndrome and controls without antiphospholipid syndrome. | J Thromb Haemost | 2026 | 42674367 | PubTator, text mining | PubMed |
| Integrative Proteomics-Metabolomics Profiling of Umbilical Cord Plasma With Machine Learning Reveals Candidate Biomarkers for Gestational Diabetes Mellitus. | Diabetes Obes Metab | 2026 | 42608332 | PubTator, text mining | PubMed |
| Plasma proteomic profiling characterizes candidate biomarkers of perimesencephalic non-aneurysmal subarachnoid hemorrhage. | J Proteomics | 2026 | 42601015 | PubTator, text mining | PubMed |
| Multi-omics analysis identifies a hepatocyte-associated signature in alcohol-related liver injury. | Front Immunol | 2026 | 42558149 | PubTator, text mining | PubMed |
| Unraveling the Multifaceted Roles of Tissue-Resident Macrophages: Focus on Bone Homeostasis and Regeneration. | Stem Cell Rev Rep | 2026 | 42545586 | PubTator, text mining | PubMed |
| Associations between postoperative serum omics-derived proteins and aggressive clinicopathological features of papillary thyroid cancer. | Sci Rep | 2026 | 42469404 | PubTator, text mining | PubMed |
| Serum Proteomics Identified the Association of Haptoglobin and Orosomucoid 1 with Disease Activity in Takayasu Arteritis. | J Inflamm Res | 2026 | 42445355 | PubTator, text mining | PubMed |
| UCA1 copy number gain in serum cfDNA predicts next-generation antiandrogen resistance in metastatic castration-resistant prostate cancer. | Sci Rep | 2026 | 42324329 | PubTator, text mining | PubMed |
| Decoding protein signatures and protein interactions in oral potentially malignant disorders: a systematic review and network analysis. | BMC Oral Health | 2026 | 42316386 | PubTator, text mining | PubMed |
| Multi-omics analysis of human patient samples identifies key immune factors in Leptospira infection. | Microbiol Spectr | 2026 | 42294721 | PubTator, text mining | PubMed |
1 to 10 of 1,766
See all 1,766 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5004
GET https://conductscience.org/api/genes/v1/5004/patents?page=2